Mice immunized with recombinant vaccinia virus (VACC) expressing Venezuelan equine encephalitis (VEE) virus capsid protein and glycoproteins El and E2 or with attenuated VEE TC-83 virus vaccine developed VEE-specific neutralizing antibody and survived intraperitoneal challenge with virulent VEE virus strains including Trinidad donkey (subtype 1AB), P676 (subtype 1C), 3880 (subtype 1D), and Everglades (subtype 2). However, unlike immunization with TC-83 virus, immunization with the recombinant VACC/VEE virus did not protect mice from intranasal challenge with VEE Trinidad donkey virus. These results suggest that recombinant VACC/VEE virus is a vaccine candidate for equines and humans at risk of mosquito-transmitted VEE disease but not for laboratory workers at risk of accidental exposure to aerosol infection with VEE virus.
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Venezuelan equine encephalitis (VEE) virus is a mosquito-borne alphavirus that produces encephalitis in equines, with fatality rates of 38 to 83% in various epidemics, and occasional encephalitis in humans (22) . Numerous VEE virus outbreaks have been recorded in South America between 1935 and 1970 (22) . In 1971, a VEE virus epidemic that originated in South America reached the United States, causing over 1,400 equine deaths in Texas (34) .
Laboratory accidents have caused at least 150 human infections with VEE virus (2) . Vaccines containing formaldehyde-treated VEE virus have caused clinical disease in 4% of vaccinees, despite extensive animal testing for residual infectious virus (3, 51) . The live, attenuated VEE TC-83 virus vaccine developed during the 1960s by serial tissue culture passage of the virulent Trinidad donkey (TRD) strain of VEE virus is avirulent for weanling mice inoculated by the intraperitoneal (i.p.) or intracerebral (i.c.) route (3) . Mice immunized with TC-83 virus resist i.p. or i.c. challenge with virulent VEE virus (3) . The attenuated TC-83 virus induces long-lasting neutralization (Nt) and hemagglutination inhibition (HI) antibodies in humans (5) and equines (11, 16, 50, 54, 56) . There are, however, several biological problems with the attenuated TC-83 virus that make it unsuitable for administration to humans at risk for VEE virus infection. Reactogenicity to the TC-83 vaccine includes fever and leukopenia in equines (21, 26, 50) and 40% of vaccinated humans (1, 37). Infection of fetal rhesus monkeys with TC-83 virus has caused congenital cerebral and ocular malformations, suggesting potential teratogenic properties (33) .
Reversion of TC-83 virus to the virulent wild type is a major concern. Serial passage of TC-83 virus in horses resulted in higher titered viremias and increased frequency and severity of clinical manifestations (35) . There was, however, no evidence of serious central nervous system infection (39) in these horses or of reversion of the vaccine virus to virulence for small laboratory animals (35 (24) . HI tests were performed as described by Lennette and Schmidt (32) . Enzyme-linked immunosorbent assay (ELISA) for anti-VEE antibodies also was used.
RESULTS
Titrations of VEE virus strains. The VEE complex is one of six recognized serologic complexes of alphaviruses (6) and is itself subdivided into six antigenic subtypes, with subtypes 1 and 3 exhibiting five and three antigenic variants, respectively (28 levels induced by VACC/TC-5A virus were stable for at least 3 months (Table 3) .
Neutralizing antibody titers were determined for both Swiss NIH and C3H mice that received 108 PFU of VACC/ TC-5A virus i.d. (Fig. 1) . The recombinant VACC/TC-5A vaccine elicited a weaker response in outbred Swiss NIH mice than in inbred C3H or A/J mice. VACC/TC-5A-induced tail lesions were also reduced in Swiss NIH mice as compared with either C3H or A/J mice.
Cross-protection studies. Five individual, high-titered anti-TC-83 or anti-VACC/TC-5A A/J mouse serum samples were pooled and tested for their ability to neutralize different antigenic subtypes of VEE virus ( Table 4 ). The Nt crossreactivities of anti-TC-83 and anti-VACC/TC-5A sera were very similar. Both sera neutralized epizootic VEE viruses 1AB and 1C (P676) efficiently. Subtype 1D (3880), 1E (Mena H), and 2 (EVE) viruses were neutralized at higher antibody concentrations. Anti-VACC/TC-5A serum Nt titers were lower than those of anti-TC-83 serum. Neither serum neutralized the distantly related VEE subtype 4 (PIX) virus or WEE virus.
Nt tests with anti-VACC/TC-5A serum indicated that the recombinant VACC/TC-5A vaccine should protect mice against challenge with subtype 1A-D and subtype 2 VEE viruses (Table 4) . To evaluate this hypothesis, C3H and Swiss NIH mice were immunized with TC-83 or recombinant virus and challenged with VEE virus (Table 5 ). Both TC-83 and VACC/TC-5A vaccine viruses protected mice against at least 6 x i05 PFU (106 IPLD50 in Swiss NIH mice) of TRD virus and 103 and i04 PFU of 3880 and P676 viruses, respectively. Although protection of Swiss NIH mice against EVE virus challenge was ambiguous because only three of eight PBS control animals died, C3H mice, which are most sensitive to EVE virus, were clearly protected by both vaccines. High challenge doses of P676 and TRD viruses caused one and two fatalities, respectively, in recombinantimmunized, but none in TC-83-immunized, Swiss NIH mice ( Table 5 ).
Protection of mice against i.n. TRD virus challenge. To determine the level of protection against aerosol infection afforded by immunization with recombinant VACC virus, mice were immunized with VACC/TC-5A virus and challenged i.n. with virulent TRD virus (100 INLD50). The VACC/TC-5A vaccine protected mice against peripheral i.p. but not i.n. challenge with TRD virus, whereas the TC-83 vaccine protected mice from challenge virus given by either route (Table 6 ). However, 5 of 20 TC-83-immunized C3H mice succumbed to i.n. TRD virus challenge. The six VACC/ TC-5A-immunized A/J mice that survived i.n. TRD virus challenge all became ill after challenge and lost weight but showed no signs of paralysis. The six A/J survivors recovered very slowly and were still not normal at 3 weeks postchallenge.
In another study, six A/J mice received 30 jig of protein A-purified, anti-VEE monoclonal antibody by injection into the tail vein. This monoclonal antibody (3B4C-4) neutralizes VEE virus to high titer (46) . Twenty-four hours after receiving the antibody, two mice were bled for antibody determination, and all six mice were challenged i.n. with 3,300 PFU (100 INLD50) of TRD virus. Despite Nt antibody titers of at least 1:1,280 in the two mice tested, the TRD virus challenge was lethal for all six mice.
DISCUSSION
We have shown that immunization with recombinant VACC (VACC/TC-5A) virus encoding the structural proteins of VEE TC-83 virus protects three strains of mice against lethal i.p. challenge with virulent VEE TRD virus. Neutralizing antibody levels in these recombinant-immunized mice correlate well with Nt titers elicited by the TC-83 vaccine in equines (26) and humans (5) . VACC/TC-5A-induced immunity appeared to be long lasting. Two recombinant vaccinia viruses (VACC/TRD-1A and VACC/TRD-20A) encoding the structural proteins of VEE TRD virus also (20, 45) .
Epidemics of VEE disease have been associated with VEE subtype 1AB and 1C viruses, which also cause significant clinical disease in experimentally infected monkeys (38) or horses (23, 55) . Mosquito-transmitted human disease has occurred with VEE subtype 2 (12) and 1D (19, 27, 58) viruses, and laboratory infection with the more distantly related VEE subtype 3 virus has been reported (9) (30, 31) . TC-83 virus can be recovered in nasopharyngeal secretions of immunized humans (37) and monkeys (38) . Replication of TC-83 virus in the nasopharynx would be expected to stimulate local secretory immunity. This stimulation may account for mouse survival after i.n. challenge with TRD virus in TC-83-immunized mice but not in mice immunized with the VACC/TC-SA recombinant vaccine. Invasion of the olfactory tract by virulent VEE virus has been demonstrated in monkeys (7, 8) and hamsters (10) . Therefore, aerosol infection may lead to central nervous system involvement by a nonhematogenous route. Although passive monoclonal Nt antibody (immunoglobulin G), protects mice from peripheral VEE virus challenge (36), we showed here that it did not protect mice from i.n. challenge. Locally stimulated immunoglobulin A production is also important in resistance to respiratory infection with rubella virus (40) , influenza virus (52) , and rhinovirus (42) .
Recombinant VACC (WR VACC strain) viruses encoding surface glycoproteins of human respiratory syncytial virus (RSV) (13, 57) and influenza A virus (48) protected rodents from i.n. challenge with RSV and influenza viruses, respectively. However, passive Nt antibody decreased replication of RSV in lungs of cotton rats but had a reduced effect on RSV replication in nasal tissues (53) . Similarly, passive antibody protected A/J mice from lethal influenza pneumonitis, but not tracheitis, after influenza A virus challenge (43) . Mice that were immunized i.d. with recombinant VACC virus expressing influenza A virus hemagglutinin developed serum anti-hemagglutinin antibodies that prevented lung, but not nasal, infection after i.n. challenge with influenza virus. Unlike the i.d. route of immunization, which failed to induce nasal secretory antibody, i.n. administration of the recombinant VACC virus elicited serum and nasal secretory anti-hemagglutinin antibodies and protected the lung and upper respiratory tract against infection by the challenge virus (49) . Thus, resistance to nasal infection appears to be dependent on nasal secretory antibody, whereas circulating antibody may be adequate to protect the lower respiratory tract. Perhaps the WR vaccinia virus strain provided greater stimulation of mucosal immunity than did the NYBH strain used in this study, since the WR strain is reported to be more invasive in mice (4) . Recently, Esposito et al. (14) reported that mice immunized with recombinant VACC-(NYBH) virus expressing the rabies virus glycoprotein survived intracranial challenge with rabies virus. Rabies virus may have been neutralized by immune serum at the inoculation site.
Although aerosol transmission of VEE virus may occur naturally under appropriate conditions (29, 59) , VEE virus infection in equines and humans is usually acquired naturally through mosquito transmission. TC-83 and VACC/TC-5A vaccine viruses both appear to protect against peripheral challenge with epidemic VEE virus strains (1AB and 1C). The recombinant VACC vaccine, however, is apparently less effective than the attenuated live TC-83 virus vaccine in protecting mice from i.n. VEE virus challenge. Recombinant virus elicited immunity that was more like that induced by formaldehyde-inactivated C-84 VEE virus vaccine (25) .
